Details

Autor(en) / Beteiligte

• Chew, Michael
• Tang, Zeyu
• Radcliffe, Christopher
• Caruana, Dennis
• Doilicho, Natty
• Ciarleglio, Maria M.
• Deng, Yanhong
• Garcia-Tsao, Guadalupe

Titel

Significant Liver Injury During Hospitalization for COVID-19 Is Not Associated With Liver Insufficiency or Death

Ist Teil von

• Clinical gastroenterology and hepatology, 2021-10, Vol.19 (10), p.2182-2191.e7

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2021

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• Coronavirus-19 disease (COVID-19) is associated with hepatocellular liver injury of uncertain significance. We aimed to determine whether development of significant liver injury during hospitalization is related to concomitant medications or processes common in COVID-19 (eg, ischemia, hyperinflammatory, or hypercoagulable states), and whether it can result in liver failure and death. There were 834 consecutive patients hospitalized with COVID-19 who were included. Clinical, medication, and laboratory data were obtained at admission and throughout hospitalization using an identified database. Significant liver injury was defined as an aspartate aminotransferase (AST) level 5 or more times the upper limit of normal; ischemia was defined as vasopressor use for a minimum of 2 consecutive days; hyperinflammatory state was defined as high-sensitivity C-reactive protein value of 100 mg/L or more, and hypercoagulability was defined as D-dimer 5 mg/L or more at any time during hospitalization. A total of 105 (12.6%) patients developed significant liver injury. Compared with patients without significant liver injury, ischemia (odds ratio [OR], 4.3; range, 2.5–7.4; P < .0001) and tocilizumab use (OR, 3.6; range, 1.9–7.0; P = .0001) were independent predictors of significant liver injury. Although AST correlated closely with alanine aminotransferase (R = 0.89) throughout hospitalization, AST did not correlate with the international normalized ratio (R = 0.10) or with bilirubin level (R = 0.09). Death during hospitalization occurred in 136 (16.3%) patients. Multivariate logistic regression showed that significant liver injury was not associated with death (OR, 1.4; range, 0.8–2.6; P = .2), while ischemic (OR, 2.4; range, 1.4–4.0; P = .001), hypercoagulable (OR, 1.7; range, 1.1–2.6; P = .02), and hyperinflammatory (OR, 1.9; range, 1.2–3.1; P = .02) disease states were significant predictors of death. Liver test abnormalities known to be associated with COVID-19 are secondary to other insults, mostly ischemia or drug-induced liver injury, and do not lead to liver insufficiency or death. [Display omitted]